David Risinger - Morgan Stanley & Co. International
Last quote by David Risinger
We believe investors underappreciate the global prospects for Pfizer's #1 growth driver Ibrance (breast cancer). We expect Ibrance to maintain its first-to-market advantage.feedback
Sep 20 2017
We can learn a lot about a person if we know what types of things he or she talks about or comments on the most frequently. There are numerous topics with which David Risinger is associated, including Keytruda, Washington, and earnings. Most recently, David Risinger has been quoted saying: “We expect Merck to return to accelerating earnings growth in 2018 after six years of flat earnings driven by Keytruda growth as Merck builds on its leadership position in immuno-oncology. Our long term estimates are well above consensus.” in the article Merck to rally 15 percent on successful cancer drug, Morgan Stanley says.
Take our quote verification challenge and find out !
Quotes by David Risinger
Jan 12 2017
We expect Merck to return to accelerating earnings growth in 2018 after six years of flat earnings driven by Keytruda growth as Merck builds on its leadership position in immuno-oncology. Our long term estimates are well above consensus.feedback
Dec 29 2016
Given recent earnings shortfalls and guidance reductions, we believe many investors want to see and assess 2017 guidance before building larger stock positions. The ability of management teams to regain investor confidence will be key to potentially better stock performance.feedback
Dec 29 2016
Several factors are likely to drive industry performance, most important Washington pricing discussions, financial results, pipeline newsflow, tax reform, and transaction activity.feedback
Check if the quote you read on social networks is authentic
This webpage has been created by a robot: errors and absent quotes cannot be totally avoided